NO994621L - Ernaeringsformuleringer inneholdende oligosakkarider - Google Patents

Ernaeringsformuleringer inneholdende oligosakkarider

Info

Publication number: NO994621L
Authority: NO; Norway
Prior art keywords: lacto; formulations containing; containing oligosaccharides; nutritional formulations; fucopentaose
Prior art date: 1997-03-31

Application number

NO994621A

Other languages

English (en)

Other versions

NO994621D0 (no

NO315682B1 (no

Inventor

Pedro A Prieto

Stephen J Kirchner

Renee M Erney

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-31

Filing date

1999-09-23

Publication date

1999-09-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25253688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994621(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-23 Application filed by Abbott Lab filed Critical Abbott Lab

1999-09-23 Publication of NO994621L publication Critical patent/NO994621L/no

1999-09-23 Publication of NO994621D0 publication Critical patent/NO994621D0/no

2003-10-13 Publication of NO315682B1 publication Critical patent/NO315682B1/no

Links

238000009472 formulation Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
235000016709 nutrition Nutrition 0.000 title abstract 2
229920001542 oligosaccharide Polymers 0.000 title abstract 2
150000002482 oligosaccharides Chemical class 0.000 title abstract 2
229940062827 2'-fucosyllactose Drugs 0.000 abstract 1
HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 abstract 1
HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 abstract 1
AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 abstract 1
WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 abstract 1
TVVLIFCVJJSLBL-SEHWTJTBSA-N Lacto-N-fucopentaose V Chemical compound O[C@H]1C(O)C(O)[C@H](C)O[C@H]1OC([C@@H](O)C=O)[C@@H](C(O)CO)O[C@H]1[C@H](O)[C@@H](OC2[C@@H](C(OC3[C@@H](C(O)C(O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)O1 TVVLIFCVJJSLBL-SEHWTJTBSA-N 0.000 abstract 1
LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 abstract 1
AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 abstract 1
SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 abstract 1
FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 abstract 1
LKOHREGGXUJGKC-GXSKDVPZSA-N alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)]-beta-D-Glcp Chemical compound C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]2O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O LKOHREGGXUJGKC-GXSKDVPZSA-N 0.000 abstract 1
CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 abstract 1
DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 abstract 1
AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 abstract 1
FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 abstract 1
FKADDOYBRRMBPP-UHFFFAOYSA-N lacto-N-fucopentaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)OC1CO FKADDOYBRRMBPP-UHFFFAOYSA-N 0.000 abstract 1
CMQZRJBJDCVIEY-UHFFFAOYSA-N lacto-N-fucopentaose III Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C1NC(C)=O CMQZRJBJDCVIEY-UHFFFAOYSA-N 0.000 abstract 1
IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 abstract 1
USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 abstract 1
229940062780 lacto-n-neotetraose Drugs 0.000 abstract 1
RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/801—Pediatric

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Polymers & Plastics (AREA)
Nutrition Science (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Food Science & Technology (AREA)
Pediatric Medicine (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Dairy Products (AREA)
Jellies, Jams, And Syrups (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Saccharide Compounds (AREA)

NO19994621A 1997-03-31 1999-09-23 Kunstige ern¶ringsformuleringer inneholdende oligosakkarider NO315682B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/829,157 US6045854A (en)	1997-03-31	1997-03-31	Nutritional formulations containing oligosaccharides
PCT/US1998/006216 WO1998043494A1 (en)	1997-03-31	1998-03-30	Nutritional formulations containing oligosaccharides

Publications (3)

Publication Number	Publication Date
NO994621L true NO994621L (no)	1999-09-23
NO994621D0 NO994621D0 (no)	1999-09-23
NO315682B1 NO315682B1 (no)	2003-10-13

Family

ID=25253688

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19994621A NO315682B1 (no)	1997-03-31	1999-09-23	Kunstige ern¶ringsformuleringer inneholdende oligosakkarider

Country Status (12)

Country	Link
US (2)	US6045854A (no)
EP (1)	EP0975235B2 (no)
JP (2)	JP4863236B2 (no)
AT (1)	ATE326862T1 (no)
CA (1)	CA2285065C (no)
DE (1)	DE69834633T3 (no)
DK (1)	DK0975235T4 (no)
ES (1)	ES2265161T5 (no)
MX (1)	MX210206B (no)
NO (1)	NO315682B1 (no)
PT (1)	PT975235E (no)
WO (1)	WO1998043494A1 (no)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19701382A1 (de) *	1997-01-16	1998-07-23	Nutricia Nv	Kohlenhydratmischung
US6329170B1 (en) *	1999-04-23	2001-12-11	Northwest Hospital	Nucleic acids and proteins of a rat ganglioside GM1-specific α1→2fucosyltransferase and uses thereof
DE19958985A1 (de) *	1999-12-07	2001-06-13	Nutricia Nv	Oligosaccharidmischung
EP1062873A1 (en) *	1999-12-13	2000-12-27	N.V. Nutricia	Improved infant formula, protein hydrolysate for use in such an infant formula, and method for producing such a hydrolysate
CA2439293A1 (en)	2001-03-05	2002-09-12	Stephen P. Ernest	Enteral formulation
DE10147100A1 (de) *	2001-09-25	2003-04-17	Numico Res B V	Antiinfektive Kohlenhydrate
DE10204000A1 (de) *	2002-02-01	2003-08-14	Nutricia Nv	Sialysierte Kohlenhydrate
WO2003101176A2 (en) *	2002-05-31	2003-12-11	Children's Hospital Medical Center	Method, composition and kit for antigenic binding of norwalk-like viruses
US7977098B2 (en) *	2002-05-31	2011-07-12	Children's Hospital Medical Center	Antigenic binding patterns of norovirus to human histo-blood group antigens
US20060014717A1 (en) *	2002-06-28	2006-01-19	Glykos Finland Oy	Therapeutic compositions for use in prophylaxis or treatment of diarrheas
CN1842277A (zh) *	2003-06-24	2006-10-04	堪萨斯大学医学中心	婴儿配方食品
WO2005055944A2 (en) *	2003-12-05	2005-06-23	Cincinnati Children's Hospital Medical Center	Oligosaccharide compositions and use thereof in the treatment of infection
ES1056525Y (es) *	2004-01-13	2004-07-16	Perez Alfredo Pineiro	Halador de tres rodillos para redes y aparejos de pesca.
ATE361101T1 (de) *	2004-08-24	2007-05-15	Nutricia Nv	Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
CA2641842A1 (en)	2006-02-10	2007-08-16	Nestec S.A.	Oligosaccharide mixture
US20110152263A1 (en) *	2006-11-16	2011-06-23	Xi Jiang	Composition and method for inhibiting norovirus infection
US8197872B2 (en) *	2007-05-17	2012-06-12	The Regents Of The University Of California	Human milk oligosaccharides to promote growth of beneficial gut bacteria
WO2009033011A1 (en)	2007-09-07	2009-03-12	Children's Hospital Medical Center	Use of secretor, lewis and sialyl antigen levels as predictors for disease
EP2060257A1 (en)	2007-11-08	2009-05-20	Nestec S.A.	Prevention and treatment of secondary infections following viral infection
MX2010005132A (es) *	2007-11-08	2010-06-02	Nestec Sa	Uso de oligosacaridos conteniendo n-acetilactosamina para maduración de las respuestas inmunes en neonatos.
EP2072052A1 (en) *	2007-12-17	2009-06-24	Nestec S.A.	Prevention of opportunistic infections in immune-compromised subjects
ES2658837T3 (es) *	2008-03-14	2018-03-12	Nestec S.A.	Mezcla simbiótica
CN102300575A (zh)	2008-12-02	2011-12-28	普罗莱克塔生物科学公司	人乳渗透物组合物及其制备和使用方法
CA2743181A1 (en) *	2008-12-19	2010-06-24	Momenta Pharmaceuticals, Inc.	Methods related to modified glycans
US8486421B2 (en)	2009-06-09	2013-07-16	Children's Hospital Medical Center	Antigen-norovirus P-domain monomers and dimers, antigen-norovirus P-particle molecules, and methods for their making and use
ES2651067T3 (es)	2009-07-06	2018-01-24	Children's Hospital Medical Center	Inhibición de la inflamación con oligosacáridos de la leche
CN102497868A (zh) *	2009-07-15	2012-06-13	N.V.努特里奇亚	用于刺激免疫系统的不可消化低聚糖的混合物
WO2011136637A1 (en)	2010-04-27	2011-11-03	N.V. Nutricia	Use of human milk oligosaccharides in infant nutrition
EP2767173A1 (en)	2010-04-27	2014-08-20	N.V. Nutricia	Use of human milk oligosaccharides in infant nutrition
WO2011150939A1 (en) *	2010-06-01	2011-12-08	Glycom A/S	Polymorphs of 2'-o-fucosyllactose and producing thereof
EP2465509A1 (en)	2010-11-23	2012-06-20	Nestec S.A.	Oligosaccharide composition for treating acute respiratory tract infections
EP2454948A1 (en) *	2010-11-23	2012-05-23	Nestec S.A.	Oligosaccharide mixture and food product comprising this mixture, especially infant formula
CA2822219C (en)	2010-12-31	2020-12-29	Abbott Laboratories	Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
MY196432A (en) *	2010-12-31	2023-04-10	Abbott Lab	Methods Of Using Human Milk Oligosaccharides For Improving Airway Respiratory Health
DK2658399T4 (da)	2010-12-31	2024-03-25	Abbott Lab	Ernæringssammensætninger omfattende humane mælkeoligosaccharider til anvendelse i behandling og/eller forebyggelse af enterisk rotavirus-infektion
BR112013016606A2 (pt)	2010-12-31	2016-09-27	Abbott Lab	processos para redução de incidência de tensão oxidante usando oligossacarídeos de leite humano, vitamina c e agentes antiflamatórios
BR112013016903A2 (pt)	2010-12-31	2019-09-24	Abbott Lab	oligossacarídeos de leite humano para modular inflamação
BR112013016587A2 (pt)	2010-12-31	2016-09-27	Abbott Lab	formulações nutricionais incluindo oligossacarídeos de leite humano e antioxidantes e usos das mesmas
US20120171166A1 (en) *	2010-12-31	2012-07-05	Abbott Laboratories	Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
MY191538A (en) *	2010-12-31	2022-06-30	Abbott Lab	Human milk oligosaccharides to promote growth of beneficial bacteria
EP2522232A1 (en) *	2011-05-13	2012-11-14	Nestec S.A.	Nutritional products comprising human milk oligosaccharides and methods for manufacture thereof
WO2012158517A1 (en)	2011-05-13	2012-11-22	Glycosyn LLC	The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
EP2526784A1 (en)	2011-05-24	2012-11-28	Nestec S.A.	Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition
PH12014500185A1 (en) *	2011-07-22	2019-10-11	Abbott Lab	Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
HK1199607A1 (en) *	2011-08-29	2015-07-10	Abbott Laboratories	Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
EP2943500B1 (en) *	2012-11-13	2017-11-08	Glycom A/S	Crystalline 3-o-fucosyllactose
WO2014090261A1 (en) *	2012-12-14	2014-06-19	Glycom A/S	Mixture of fucosylate lactoses
EP2745705A1 (en) *	2012-12-18	2014-06-25	Abbott Laboratories	Nutritional use of human milk oligosaccharides
US10626460B2 (en)	2013-02-21	2020-04-21	Children's Hospital Medical Center	Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
DK2999358T3 (en)	2013-05-22	2021-10-11	Glycom As	Synthetic mixture of oligosaccharides for the treating a microbiota of a mammal
US9321803B2 (en)	2013-07-12	2016-04-26	Children's Hospital Medical Center	Compositions and methods for inhibiting norovirus infection
EP3111942B1 (en) *	2013-11-15	2021-01-06	Société des Produits Nestlé S.A.	Compositions for use in the prevention or treatment of urt infections in infants or young children at risk
HK1231398A1 (zh)	2014-04-08	2017-12-22	Abbott Laboratories	使用人乳寡糖增强对病原体的粘膜先天免疫反应和/或检测的方法
MX377227B (es)	2014-09-25	2025-03-07	Soc Des Produits Nestle S A Star	Sistema de formulas infantiles con niveles adaptables de oligosacaridos de la leche humana (hmo).
PL3209673T5 (pl)	2014-10-24	2023-10-23	Glycom A/S	Mieszaniny hmo
AU2015340652B9 (en) *	2014-10-31	2020-04-16	Société des Produits Nestlé S.A.	Composition comprising Fut2-dependent oligosaccharides and lacto-n-neotetraose for use in promoting brain development and cognition
CN107404925A (zh) *	2015-03-05	2017-11-28	雀巢产品技术援助有限公司	用于预防或治疗婴儿或幼儿胃肠感染/炎症的组合物
CN107427054A (zh) *	2015-03-05	2017-12-01	雀巢产品技术援助有限公司	用于预防或治疗婴儿或幼儿的耳炎或支气管炎的组合物
EP3288389A4 (en)	2015-04-28	2018-10-10	Children's Hospital Medical Center	Use of oligosaccharide compositions to enhance weight gain
ES2772685T3 (es) *	2015-08-04	2020-07-08	Nestle Sa	Composiciones nutricionales con 2FL y LNNT para inducir una microbiota intestinal similar a la de los bebés lactantes
EP3389668A4 (en)	2015-12-15	2019-08-21	Glycom A/S	MIXTURE OF HMOS
CN108495635A (zh) *	2016-01-26	2018-09-04	雀巢产品技术援助有限公司	人乳低聚糖对抗日后的脂肪量过度积聚和相关的健康障碍
AU2017211272B2 (en) *	2016-01-26	2022-04-21	Société des Produits Nestlé S.A.	Human milk oligosaccharides for health benefits by prevention of premature adiposity rebound
BR112019005329A2 (pt) *	2016-09-19	2019-06-18	Prolacta Bioscience, Inc.	composições de oligossacarídeos de leite humano purificadas
US20180103675A1 (en)	2016-10-14	2018-04-19	Mead Johnson Nutrition Company	Personalized pediatric nutrition products comprising human milk oligosaccharides
US10980269B2 (en) *	2016-12-12	2021-04-20	Mead Johnson Nutrition Company	Protein hydrolysates and methods of making same
EP3600397A4 (en)	2017-03-28	2021-01-27	Children's Hospital Medical Center	NOROVIRUS PARTICLE VACCINES AND THEIR MANUFACTURING AND USE PROCEDURES
MX2019011334A (es)	2017-05-24	2019-10-30	Nestle Sa	Composicion que comprende oligofructosa (of) para usar en la mejora de la memoria a corto plazo y otros beneficios congnitivos.
MX2019011445A (es)	2017-05-24	2019-11-18	Nestle Sa	Composicion que comprende oligosacaridos de la leche humana (hmo) para usar en la mejora de la memoria a corto plazo y otros beneficios cognitivos.
EP3648617A1 (en) *	2017-07-07	2020-05-13	Société des Produits Nestlé S.A.	Human milk fortifier
US20200221749A1 (en)	2017-07-07	2020-07-16	Societe Des Produits Nestle S.A.	Human milk fortifier
CN111093395A (zh)	2017-07-07	2020-05-01	雀巢产品有限公司	人乳强化剂
US11197917B2 (en)	2017-12-01	2021-12-14	ByHeart, Inc.	Formulations for nutritional support in subjects in need thereof
EP3524067B1 (en)	2018-02-08	2025-04-02	Chr. Hansen HMO GmbH	Spray-dried mixture of human milk oligosaccharides
EP3546060A1 (en) *	2018-03-27	2019-10-02	DuPont Nutrition Biosciences ApS	Process for spray drying fucosyllactose solutions and related product compositions
WO2019160922A1 (en) *	2018-02-19	2019-08-22	Dupont Nutrition Biosciences Aps	Process for spray drying fucosyllactose solutions and related product compositions
WO2020001863A1 (en)	2018-06-25	2020-01-02	Societe Des Produits Nestle S.A.	Composition comprising human milk oligosaccharides for use in improving, enhancing, promoting or modulating a gabaergic function in the central nervous system
WO2020001862A1 (en)	2018-06-25	2020-01-02	Societe Des Produits Nestle S.A.	Composition comprising human milk oligosaccharides for use in improving, enhancing, promoting or modulating a serotonergic function in the central nervous system
AU2019409528B2 (en) *	2018-12-20	2025-04-24	Société des Produits Nestlé S.A.	Human milk fortifier composition
EP3934656A1 (en) *	2019-03-05	2022-01-12	Société des Produits Nestlé S.A.	A nutritional composition for use to enhance executive function
WO2020245313A1 (en) *	2019-06-04	2020-12-10	N.V. Nutricia	Nutritional composition comprising 2'fucosyllactose and 3'galactosyllactose
WO2021015977A1 (en) *	2019-07-23	2021-01-28	Dupont Nutrition Biosciences Aps	Oral healthcare treatment and related compositions
ES1240969Y (es) *	2019-09-18	2020-07-30	Jennewein Biotechnologie Gmbh	Composiciones de cereales que contienen oligosacaridos de la leche humana
JP2022548785A (ja)	2019-09-24	2022-11-21	プロラクタバイオサイエンス，インコーポレイテッド	炎症性疾患及び免疫疾患の治療のための組成物及び方法
GB2590375B (en) *	2019-12-11	2024-05-08	Mjn Us Holdings Llc	Staged nutritional compositions containing human milk oligosaccharides and uses thereof
TW202233201A (zh)	2020-12-16	2022-09-01	荷蘭商弗里斯蘭康必奶荷蘭有限公司	包含ＬＮＦＰＩＩＩ和ＬＳＴａ的合成組成物
EP4346450B1 (en)	2021-06-04	2025-02-26	N.V. Nutricia	Infant formula for feeding infants receiving infant formula and human breast milk

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5951264B2 (ja) *	1981-11-30	1984-12-13	雪印乳業株式会社	オリゴ糖含有粉末の製造方法
DD273543A3 (de) *	1987-09-14	1989-11-22	Univ Rostock	Verfahren zur herstellung von saeuglings- und diaetnahrungen mit hypoantigener, bifidogener wirkung
SE462134B (sv) *	1987-10-22	1990-05-14	Biocarb Ab	Livsmedel innehaallande lacto-n-tetraos och foerfarande foer dess framstaellning
DE3876986D1 (de) *	1988-07-07	1993-02-04	Milupa Ag	Verfahren zur enzymatischen herstellung von bifidogener saeuglings- und diaetnahrung.
US5095106A (en) *	1989-07-25	1992-03-10	Colgate-Palmolive	Olgiosaccharide inhibition of Streptococcus pyogenes adhesion
WO1991016449A1 (en) *	1990-04-16	1991-10-31	The Trustees Of The University Of Pennsylvania	Saccharide compositions, methods and apparatus for their synthesis
US5021245A (en) *	1990-05-22	1991-06-04	Abbott Laboratories	Infant formula containing a soy polysaccharide fiber source
CN1129953A (zh) *	1993-07-15	1996-08-28	尼奥斯药品公司	糖组分的合成方法
US5750176A (en) *	1994-03-09	1998-05-12	Abbott Laboratories	Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
JPH0838064A (ja) *	1994-07-26	1996-02-13	Meiji Seika Kaisha Ltd	有害細菌の感染を予防する飼料
US5545553A (en) *	1994-09-26	1996-08-13	The Rockefeller University	Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5827526A (en) *	1995-07-11	1998-10-27	Abbott Laboratories	Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans

1997
- 1997-03-31 US US08/829,157 patent/US6045854A/en not_active Expired - Lifetime
1998
- 1998-03-30 WO PCT/US1998/006216 patent/WO1998043494A1/en not_active Ceased
- 1998-03-30 AT AT98912118T patent/ATE326862T1/de active
- 1998-03-30 DK DK98912118.1T patent/DK0975235T4/da active
- 1998-03-30 ES ES98912118.1T patent/ES2265161T5/es not_active Expired - Lifetime
- 1998-03-30 EP EP98912118.1A patent/EP0975235B2/en not_active Expired - Lifetime
- 1998-03-30 CA CA2285065A patent/CA2285065C/en not_active Expired - Lifetime
- 1998-03-30 PT PT98912118T patent/PT975235E/pt unknown
- 1998-03-30 JP JP54189298A patent/JP4863236B2/ja not_active Expired - Fee Related
- 1998-03-30 DE DE69834633.5T patent/DE69834633T3/de not_active Expired - Lifetime
- 1998-12-18 US US09/216,056 patent/US6146670A/en not_active Expired - Lifetime
1999
- 1999-09-23 NO NO19994621A patent/NO315682B1/no not_active IP Right Cessation
- 1999-09-29 MX MX9908953A patent/MX210206B/es unknown
2011
- 2011-09-07 JP JP2011195159A patent/JP2012036192A/ja active Pending

Also Published As

Publication number	Publication date
US6045854A (en)	2000-04-04
JP2001517949A (ja)	2001-10-09
EP0975235B1 (en)	2006-05-24
DE69834633D1 (de)	2006-06-29
EP0975235A1 (en)	2000-02-02
US6146670A (en)	2000-11-14
WO1998043494A1 (en)	1998-10-08
MX9908953A (es)	2000-01-31
ATE326862T1 (de)	2006-06-15
CA2285065C (en)	2011-07-19
DE69834633T3 (de)	2014-05-08
NO994621D0 (no)	1999-09-23
ES2265161T3 (es)	2007-02-01
DE69834633T2 (de)	2007-05-03
JP4863236B2 (ja)	2012-01-25
CA2285065A1 (en)	1998-10-08
EP0975235B2 (en)	2014-01-15
DK0975235T3 (da)	2006-10-02
MX210206B (es)	2002-09-06
ES2265161T5 (es)	2014-03-24
NO315682B1 (no)	2003-10-13
JP2012036192A (ja)	2012-02-23
PT975235E (pt)	2006-10-31
DK0975235T4 (da)	2014-03-31

Legal Events

Date	Code	Title	Description
2014-11-03	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
PT975235E (pt)	2006-10-31	Formulacoes nutricionais contendo oligossacaridos
FI973828A0 (fi)	1997-09-29	Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
CA2339765A1 (en)	2000-02-17	Compounds and compositions for delivering active agents
EP0783299A4 (en)	1999-06-30	COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
YU23599A (sh)	2001-07-10	Stabilizovani antihistaminski sirup
PE44895A1 (es)	1995-12-20	Compuesto derivado de benzotiofeno que puede inhibir la perdida osea y disminuir el colesterol en suero
NO20001105L (no)	2000-05-05	Transgene pattedyr som danner oligosakkarider i melken
IL140710A0 (en)	2002-02-10	Pulmonary delivery of active agents
EP0698031A4 (en)	1997-07-09	SIALYL LE x ANALOGUES AS INHIBITORS OF CELLULAR ADHESION
BG103930A (en)	2000-07-31	Eletriptan hemisulphate and caffeine containing pharmaceutical compositions
BG102259A (en)	1998-09-30	Compostions with controlled paroxetine release
ZA966964B (en)	1997-02-19	Compositions having synergistic fungitonix effects.
AU8332791A (en)	1992-03-02	Oral pharmaceutical compositions containing melatonin
AU1945495A (en)	1995-10-03	Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
BG102342A (en)	1998-09-30	Optical active derivative of phenylpyrimidine as an anlgesics
HUP9801133A3 (en)	2000-03-28	1,2,4-triazole-derivatives, fungicide compositions containing these compounds as active ingredients
IL127851A0 (en)	1999-10-28	Inhibition of TNF activity
SG181694G (en)	1995-05-12	Solid oral administration forms containing ifosfamide as active agent
HUP0004362A2 (hu)	2001-08-28	Karbamazepint vagy származékait tartalmazó parenterális készítmények
ES2170377T3 (es)	2002-08-01	Composicion que contiene quitosana.
ES2183346T3 (es)	2003-03-16	Sistemas conjugados de bis-fosfonato con restos alquilantes que tienen actividad antitumoral.
BG103779A (en)	2000-06-30	Crystallohydrate sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidine-3-ilidenmethyl)-1h-i ndole-2-carboxylic acid
BR9907195A (pt)	2000-10-10	" formulações de tiagabina de liberação prolongada com efeitos colaterais reduzidos "
FR2685204B1 (fr)	1995-06-16	Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine.
CA2183745A1 (en)	1995-09-28	Detergent Compositions